1. In Vivo
  2. >>Market Access

Trump's Sights Set On Payers And Pharmas, But Medtechs Must Not Be Complacent

 
• By Ashley Yeo

It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.

Capitol House

A month after Donald Trump's election as US President last November, In Vivo asked Brian Chapman, ZS Associates' principal and leader of the firm's medical products consulting practice, for an early take on how medtech businesses and the sector in general would be affected by decisions likely to emerge from the new US administration and its three-line Republican monopoly. (Also see "US Medtech Under Trump: Below The Radar Or In The Line Of Fire?" - In Vivo, 12 December, 2016.)

At that early stage, it was hard to make any predictions, although the laser focus was already on insurance reform....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy